Company Overview and News

 
Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer

2018-10-15 globenewswire
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today announced the appointment of Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer (“CMO”). Dr. Sersch will oversee the clinical development of Mustang’s pipeline in CAR T technology and gene therapies.
MBIO

6
Mustang Bio Sees Hammer Chart Pattern: Time to Buy?

2018-09-07 zacks - 1
Mustang Bio, Inc. (MBIO - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because MBIO recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
MBIO AVGO KHC MCFT BRCM

1
Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018

2018-09-04 globenewswire - 1
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today announced oral and poster presentations related to its CAR T therapies at the 4th Annual CAR-TCR Summit 2018, to be held September 4-7, 2018, at the Seaport Hotel & World Trade Center in Boston.
MBIO FBIO

 
MBIO / Mustang Bio, Inc. null

2018-08-25 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,S M,#7!E+UA2968O5ULQ(#(@,5T^/G-T
MBIO

 
MBIO / Mustang Bio, Inc. null

2018-08-25 sec.gov
90 Park Avenue New York, NY 10016 212-210-9400 | Fax: 212-210-9444
MBIO

 
MBIO / Mustang Bio, Inc. null

2018-08-25 sec.gov
Mustang Bio, Inc. July 24, 2018 Securities and Exchange Commission Department of Corporation Finance
MBIO

 
Mustang Bio: Prudent Expansion Into Gene Therapy

2018-08-24 seekingalpha
Mustang is brewing a differentiated form of chimeric antigen receptor/T-cell receptor (CAR-T) having key advantages over conventional molecules.
MBIO FBIO ONCE

12
bluebird bio: Heading To $200 On Pipeline Progress And Potential M&A

2018-08-22 seekingalpha - 1
bluebird bio is a clinical-stage biotechnology company focussed on gene therapy, cancer immunopathy and gene editing for the treatment of cancer and rare diseases.
MBIO REGN GILD JUNO BLUE CELG NVS KITE BLUE CR

2
Mustang Bio and St. Jude Children’s Research Hospital to Work on Gene Therapy Together

2018-08-14 biospace - 2
Mustang Bio, Inc., located in New York City, and St. Jude Children's Research Hospital, in Memphis, Tennessee, have signed an exclusive worldwide license deal to develop a first-in-class lentiviral gene therapy for X-linked severe combined immunodeficiency (X-SCID).
MBIO FBIO

41
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review

2018-08-14 seekingalpha - 1
Discussion: RedHill Biopharma (RDHL) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The notice allows the patent to be valid until at least 2029. Apart from Crohn’s Disease, the company has diverse program pipeline. The program includes other indications such as H. Pylori infection, migraine, and nontuberculous mycobacteria (NTM) infections.
MBIO REDIF APOP RDHL ACER ARQL MGTX STML CLRBZ CLRBW MCUJF ABBV CLRB APOPW ALNY ABBV VNRX

 
MBIO / Mustang Bio, Inc. FORM 8-K (Current Report)

2018-08-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MBIO

 
Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

2018-08-13 globenewswire
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2018.
MBIO FBIO

 
MBIO / Mustang Bio, Inc. FORM 10-Q (Quarterly Report)

2018-08-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSIO
MBIO

1
Reuters Issues Special Report Citing Conflict of Interest by Biotech Incubator

2018-08-07 biospace - 1
Reuters recently issued a special report focusing on National Securities Corp., alleging conflicts of interest when the company’s analysts recommend certain biotech companies. The allegations essentially note the company analysts recommending biotech companies that National has significant ownership or financial interests in without disclosing that fact.
ATXI MBIO NHLD CKPT FBIO

 
Mustang Bio: What The Latest Development For MB-102 Entails

2018-07-29 seekingalpha
Mustang Bio is perhaps the most promising subsidiary of Fortress Biotech. Chimeric antigen receptor/T-cell receptor (CAR-T) is a stellar approach to cancer treatment with the superb efficacy and safety.
MBIO EXEL FBIO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to MBIO / Mustang Bio, Inc. on message board site Silicon Investor.

Cambior Gold (CBJ) Cambior Gold (CBJ) Cambior Gold (CBJ) CBJ: Cambior, Inc. CBJ: Cambior, Inc. CBJ: Cambior, Inc.
Cambior Mining Inc. Cambior Mining Inc. Cambior Mining Inc. CAMB (Cambio, Inc., OTC-BB) CAMB (Cambio, Inc., OTC-BB) CAMB (Cambio, Inc., OTC-BB)
Megabios (MBIO) Megabios (MBIO) Megabios (MBIO)
CUSIP: 62818Q104